Development of novel therapeutics for all individuals with CF (the future goes on)

J Cyst Fibros. 2023 Mar:22 Suppl 1:S45-S49. doi: 10.1016/j.jcf.2022.10.007. Epub 2022 Oct 30.

Abstract

Despite the major advances and successes in finding and establishing new treatments that tackle the basic defect in Cystic Fibrosis (CF), there is still an unmet need to bring these potentially curative therapies to all individuals with CF. Here, we review aspects of what is still missing to treat all individuals with CF by such approaches. On the one hand, we discuss novel holistic (high-throughput) approaches to elucidate mechanistic defects caused by distinct classes of mutations to identify novel drug targets. On the other hand, we examine therapeutic approaches to correct the gene in its own environment, i.e., in the genome.

Keywords: CFTR; Cystic fibrosis; Genome editing; Theratypes.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis* / drug therapy
  • Drug Delivery Systems
  • Genetic Therapy
  • Humans
  • Mutation

Substances

  • Cystic Fibrosis Transmembrane Conductance Regulator